Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
11 mars 2021 16h10 HE
|
Adicet Bio
Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an anti-CD20 allogeneic CAR gamma-delta T cell therapy, interim clinical data expected in...
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors
04 mars 2021 16h01 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
16 févr. 2021 07h00 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...
Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement
10 févr. 2021 07h51 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...
Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
09 févr. 2021 16h04 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...
Adicet Bio to Participate in Upcoming Investor Conferences
07 janv. 2021 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
08 déc. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for...
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
01 déc. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Bio to Participate in Upcoming Investor Conferences
06 nov. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer
26 oct. 2020 16h10 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...